SCHEMBL29913249

SCHEMBL29913249

CCc1nc(N)nc(N)c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2D6 P10635 2/20 0.73
CYP2C9 P11712 2/20 0.73
CYP2C19 P33261 1/20 0.73
HEXA P06865 6/20 0.71
HEXB P07686 6/20 0.71
DHFR P00374 4/20 0.65
MEN1 O00255 1/20 0.52
SLC22A1 O15245 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
HTR1A P08908 1/20 0.52
ADRA2A P08913 1/20 0.52
HTR2A P28223 1/20 0.52
ADRA1A P35348 1/20 0.52
HTR2B P41595 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8739389 0.84 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL29913110 0.83 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL12368243 0.83 HEXA (1.00) CYP1A2CYP3A4CYP2D6CYP2C9HEXA
SCHEMBL29913337 0.81 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL12368253 0.80 HEXA (1.00) CYP1A2CYP3A4CYP2D6CYP2C9HEXA
SCHEMBL29913145 0.79 DHFR (1.00) CYP1A2CYP3A4CYP2D6CYP2C9HEXA
SCHEMBL11881285 0.79 DHFR (1.00) CYP1A2CYP3A4CYP2D6CYP2C9HEXA
SCHEMBL3498787 0.78 HEXA (1.00) CYP1A2CYP3A4CYP2D6CYP2C9HEXA
SCHEMBL12137690 0.76 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL29913166 0.76 HEXA (0.81) CYP1A2CYP3A4CYP2D6CYP2C9HEXA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289686-A1 COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF WASHINGTON UNIVERSITY 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289686-A1 COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF KEAP1, GSTK1, NFE2L2 CYP1A2 4391/4885CYP3A4 4677/4885CYP2D6 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.